This study aims to identify the secondary metabolite compounds and to test the antioxidant activity of ethanol extract, n-hexane fraction, and chloroform fraction of Hippobroma longiflora leaves. Extraction was carried out by the maceration method using ethanol. The resulting crude ethanol extract was then partitioned with n-hexane and chloroform. Each extract and fraction was then tested by phytochemical screening. Antioxidant activity testing was carried out using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) method. The phytochemical screening test showed that the ethanol extract contained flavonoids, saponins, triterpenoids, and alkaloids; the n-hexane fraction contained steroids, and alkaloids; and the chloroform fraction contained flavonoids, steroids, and alkaloids. Analysis of the antioxidant activity revealed the following Inhibitory Concentration (IC50 values): 9.57 ppm of ethanol extract, 99.59 ppm of n-hexane fraction, 48.54 ppm of chloroform fraction, and 4.30 ppm of ascorbic acid. Based on these results, the antioxidant activity of the ethanol extract was more potential than the n-hexane and chloroform fractions, but smaller than ascorbic acid.

Background: Dyslipidemia is a lipid metabolism disorder characterized by elevated levels of total cholesterol, Low Density Lipoprotein (LDL) and triglycerides and a decrease in high-density lipoprotein (HDL). Meniran contains tannins, saponins, alkaloids, rutin and quercetin, which have hypolipidemia effect. Objective: This study aimed to observe the effect of meniran extract on the Low Density Lipoprotein (LDL) in Wistar rats, compared with simvastatin. Methods: Thirty-five Wistar rats (Rattus novergicus) were divided into five groups, then all were induced with American Diet 2 (AD2) high fat modification diet for 60 days, except the control group I. Then during the next 60 days, groups I and II were not given any treatment, group III was given simvastatin 0.8 mg/200 g body weight (BW)/ day, group IV was given meniran extract 50 mg/200 g BW/day and group V was given meniran extract 100 mg/200 g BW/day. Results: Meniran therapy 50 mg/200 g BW/day was better in lowering LDL level than meniran dose 100 mg/200 g BW/day. Meniran therapy, which was significantly (p<0.05) better than simvastatin, was meniran dose of 50 mg/200 g BW/day in lowering LDL. Conclusion: Meniran therapy 50 mg/200 g BW/day can lower LDL level significantly. In this dose meniran decreased LDL better than simvastatin.